Showing results (11-20 of 76) with videos related to
Sort By:
Pageof 8
Oncoimmunology|May 1, 2023
Early response evaluation of PD-1 blockade in NSCLC patients through FDG-PET-CT and T cell profiling of tumor-draining lymph nodesFrank J Borm, Jasper Smit, Joyce Bakker, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 18, 2008
Reproducibility of tumor perfusion measurements using 15O-labeled water and PETAdrianus J de Langen, Mark Lubberink, Ronald Boellaard, et al.Therapeutic Drug Monitoring|June 22, 2023
Clinical Relevance of High Plasma Trough Levels of the Kinase Inhibitors Crizotinib, Alectinib, Osimertinib, Dabrafenib, and Trametinib in NSCLC PatientsLishi Lin, Hannerieke J Barkman, Egbert F Smit, et al.Targeted Oncology|December 11, 2021
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical PracticeLishi Lin, Egbert F Smit, Adrianus J de Langen, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 28, 2018
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion-Positive Advanced NSCLCBianca van Veggel, Adrianus J de Langen, Sayed M S Hashemi, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 17, 2010
Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancerVirginie Frings, Adrianus J de Langen, Egbert F Smit, et al.Cancers|July 2, 2021
Response Prediction and Evaluation Using PET in Patients with Solid Tumors Treated with ImmunotherapyFrank J Borm, Jasper Smit, Daniela E Oprea-Lager, et al.Lung Cancer (Amsterdam, Netherlands)|October 1, 2018
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responsesBianca van Veggel, Adrianus J de Langen, Sayed Hashemi, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 19, 2011
Effects of image characteristics on performance of tumor delineation methods: a test-retest assessmentPatsuree Cheebsumon, Floris H P van Velden, Maqsood Yaqub, et al.British Journal of Cancer|August 1, 2018
Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatmentAdrianus J de Langen, M Jebbink, Sayed M S Hashemi, et al.Pageof 8